AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

On October 20, 2025 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), reported it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the conference, members of management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the Company’s Maxim Growth Summit presentation slide deck, please visit the Presentations page on aimimmuno.com.

For more information and a complete agenda of the Maxim Growth Summit, please visit www.maximgrp.com/2025-growth-summit.

(Press release, AIM ImmunoTech, OCT 20, 2025, View Source [SID1234656809])

FDA Grants Fast Track Designation to TAC-001

On October 20, 2025 Tallac Therapeutics reported that the U.S. Food and Drug Administration has granted Fast Track designation to TAC-001 for the treatment of previously treated, locally advanced unresectable or metastatic cholangiocarcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cholangiocarcinoma (CCA) is an aggressive malignancy of the biliary tract with a poor overall prognosis and limited treatment options. The majority (~70%) of patients are diagnosed late at advanced stages and have a 5-year survival rate of less than 10%. Current treatment options, particularly for patients who relapsed after prior systemic treatment, are limited. The designation highlights TAC-001’s potential to address this urgent medical need.

Building on encouraging safety and efficacy Ph1 data in solid tumors, the Fast Track designations will greatly support the clinical development strategy to advance TAC-001, a next-generation antibody-drug conjugate (ADC) designed to safely and efficiently engage both the innate and adaptive anti-tumor immune response.

(Press release, Tallac Therapeutics, OCT 20, 2025, View Source [SID1234656825])

Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025

On October 20, 2025 Kivu Bioscience, a biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, reported that it will present new preclinical activity and safety data for KIVU-107, a best-in-class PTK7-targeting ADC, at the 16th World ADC San Diego, held November 3-6, 2025. The data will be featured in both an oral and poster presentation highlighting the unique biophysical and therapeutic properties of KIVU-107, and its potential to set a new standard among next-generation ADCs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KIVU-107 is a PTK7-targeting ADC generated via site-specific GlycoConnect and HydraSpace conjugation technologies. It is designed to be highly stable in circulation, with negligible free payload release, maximizing on-tumor activity while minimizing off-target toxicity. The ADC leverages an exatecan payload (SYNtecan E) with an optimized drug-antibody ratio (DAR), resulting in a wider therapeutic index and deeper, more durable responses in preclinical tumor models.

"These preclinical data highlight the potential of KIVU-107 as a next-generation ADC designed to deliver enhanced efficacy, superior stability, and improved tolerability," said Mohit Trikha, Ph.D., President and Chief Operating Officer, Kivu Bioscience. "In preclinical studies, KIVU-107 is both highly potent and exceptionally well-tolerated, a combination that’s rare among ADCs. We look forward to initiating our Phase 1 clinical trial this quarter."

Both the oral and poster presentations feature preclinical data highlighting KIVU-107’s strong anti-tumor activity, and excellent safety profile. KIVU-107 demonstrated potent antigen-specific cytotoxicity with rapid internalization in vitro and. in mouse xenograft models, durable complete tumor regressions were observed after a single dose. KIVU-107 also showed robust activity in combination with olaparib and in ADC-resistant patient-derived xenograft models, supporting its potential to overcome resistance mechanisms seen with current ADC therapies.

Repeat-dose GLP toxicology studies in non-human primates demonstrated favorable pharmacokinetics, minimal unconjugated exatecan exposure, and an exceptional tolerability profile supporting a potential higher starting dose for first-in-human evaluation. Together, these findings confirm a wide therapeutic index and a best-in-class potential for efficacy, stability, and safety.

The preclinical data collectively demonstrate that KIVU-107 combines precision targeting with a potent and controllable payload, resulting in a differentiated ADC profile with a remarkably wide therapeutic index.

Presentation Details:

Oral Presentation

Title: Striving for Kinder and Gentler ADCs: Spotlight on Solid Tumor Target and Preclinical Development of KIVU-107
Presenter: Mohit Trikha, Ph.D.
Session: Discovery Biology
Date/Time: Tuesday, November 4, 3:00 PM PT
Poster Presentation

Title: Preclinical Efficacy and Safety of KIVU-107, a Novel PTK7-Targeting Antibody-Drug Conjugate (ADC)
Authors: N. Viller, L. Zhang, X. Jiang, A. MacLaren, M. Trikha
Session: Day 2 Poster Session
Poster Number: 84
Date/Time: Wednesday, November 5, 8 AM – 6 PM PT

(Press release, Kivu Bioscience, OCT 20, 2025, View Source [SID1234656841])

RUTI® in combination with BCG Therapy Show Encouraging Outcomes in Bladder Cancer

On October 20, 2025 Archivel Farma reported the outcome of RUTIVAC study in Bladder Cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The RUTI vaccine, developed and produced in-house by Archivel Farma, was tested in a phase I trial involving 40 patients with high-risk non-muscle-invasive bladder cancer at Hospital Universitari Germans Trias i Pujol. Administered prior to standard BCG therapy, RUTI enhanced the immune response, reducing tumor recurrence and progression, and improving patient survival over five years.

The vaccine generated stronger CD4⁺ and CD8⁺ T-cell responses and increased cytokine production, without promoting immunosuppressive T-regulatory cells. Importantly, RUTI was well tolerated with only mild injection-site reactions.
These promising results, published in European Urology, suggest that RUTI could enhance the current standard of care for bladder cancer, paving the way for larger trials to confirm its clinical benefits. Read in View Source

Archivel Farma has been both, sponsor and RUTI supplier for this study. We extend our sincere thanks and congratulations to our partners, IrsiCaixa and the Germans Trias i Pujol Research Institute (IGTP), for their dedication and excellent work.

(Press release, Archivel Farma, OCT 20, 2025, View Source [SID1234656810])

Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors

On October 20, 2025 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class antibodies for cancer immunotherapy, reported a poster at the 2025 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting on updated clinical results and positive antitumoral activity of BT-001 in patients with advanced refractory tumors.

The data show that intra-tumoral (IT) BT-001 injection in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) intravenous (IV) anti-PD-1 therapy KEYTRUDA (pembrolizumab[1]), was well tolerated and showed positive local, abscopal and sustained antitumoral activity in injected and non-injected lesions.

Translational analyses reveal increased T cell chemoattractants in the blood and infiltration of activated CD8+ T cells and macrophages in tumors after treatment with BT-001 in combination with pembrolizumab. Significant tumor shrinkage (≥30% decrease in longest diameter) was observed in five of 16 injected lesions (in three patients with melanoma and one patient with sarcoma). Four patients had tumor shrinkage of non-injected lesions.

Long-lasting partial responses (PRs) were observed in a patient with melanoma resistant to anti-PD-1/anti-CTLA-4 combination therapy and in a heavily pre-treated, PD-L1 negative leiomyosarcoma patient.

These immune-mediated tumor shrinkages are consistent with the mechanistic hypothesis that BT-001, in combination with pembrolizumab, turns "cold" tumors into immunologically active ones. The overall data support further development of BT-001 across a range of solid tumors to improve responses to cancer immunotherapies.

Prof. Celeste Lebbé, Dermatologist and Venereologist, Head of Dermatology Department at Hospital Saint-Louis, Paris, commented: "Many cancer patients fail to respond to existing treatments, emphasizing the urgent need for new approaches. BT-001 represents a promising new class of immunotherapy, capable of inducing a potent local immune response through the expression of GM-CSF and an anti-CTLA-4 antibody. These clinical data provide compelling proof of concept, highlighting the relevance of this oncolytic virus in transforming cold tumors into immunologically active ones. Whether administered alone or in combination with pembrolizumab, BT-001 offers the potential to expand treatment options with a favorable safety profile across multiple tumor types."

Dr. Alessandro Riva, Chairman and CEO of Transgene, said: "We are pleased to jointly present these clinical data on BT-001 at ESMO (Free ESMO Whitepaper) 2025, demonstrating encouraging antitumor activity in patients with solid, refractory solid tumors. These updated results confirm BT-001’s mechanism of action as a single agent administered via intra-tumoral injection and show early signs of clinical benefit, including lesion shrinkage and stable disease. With a favorable safety profile – both alone and in combination with pembrolizumab – BT-001 could represent an effective option to enhance responses to immune checkpoint inhibitors (ICI) in patients with limited treatment alternatives. Together with our partner BioInvent, we will continue to explore its safety and efficacy and share further data as it becomes available."

Andres McAllister, MD, PhD, Chief Medical Officer at BioInvent, added: "By combining BT-001 with pembrolizumab, we are building upon the promising data generated by BT-001 as a single agent. Targeting the PD-1/PD-L1 pathway in addition to BT-001’s mechanism of action is expected to further stimulate and restore the patient’s immune system, which should result in improved antitumoral activity and patient outcome. We are pleased to pursue clinical development opportunities with clinicians and further demonstrate the potential of this novel oncolytic virus."

Transgene and BioInvent are co-developing BT-001, an oncolytic virus developed using Transgene’s Invir.IO platform armed to express GM-CSF and BioInvent’s full-length anti-CTLA-4 monoclonal antibody, to elicit a strong and effective anti-tumoral response in solid tumors.

The poster titled: "Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered in combination with pembrolizumab in patients with advanced solid tumors.", can be accessed at the websites for the ESMO (Free ESMO Whitepaper) conference, Transgene and BioInvent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Transgene, OCT 20, 2025, https://www.bioinvent.com/en/press/transgene-and-bioinvents-armed-oncolytic-virus-bt-001-shows-positive-local-abscopal-and [SID1234656826])